CHANGES IN TUMOR NECROSIS FACTOR ALFA DURING TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS BY TRANSIMMUNIZATION METHOD

Cover Page


Cite item

Abstract

Background: Despite the availability of a  large number of treatments for multiple sclerosis with various targets, these treatments are not always effective. According to the literature, experimental studies have shown a  significant decrease in tumor necrosis factor alfa (TNF-α) with the use of extracorporeal photochemotherapy. Aim: To assess changes in TNF-α in patients with multiple sclerosis during treatment with transimmunization. Materials and methods: The study recruited 13 adult patients with multiple sclerosis. Serum TNF-α was measured by immunochemiluminescence analysis (IMMULITE 1000, Siemens). The patients were treated by transimmunization, i.e. a  modified photopheresis. Two hours before the procedure, Ammifurin (8-methoxypsoralene) was administered to all the patients, then their mononuclear cells were isolated under PBSC protocol with Haemonetics MCS+ cell separator. Thereafter, mononuclear cells were irradiated with ultraviolet for 90  minutes and incubated for 20 hours at 37 °С. The next day the cells were re-infused to the patients. The procedure was performed 2  times per week for 6  months, then once per 4  months. Results: Before transimmunization, mean TNF-α level in adult patients with multiple sclerosis was 9.958±0.812  pg/mL (normal, below 8.1 pg/mL). After transimmunization, its level was 6.992±0.367  pg/mL (р<0.05). Conclusion: Ultraviolet irradiation of peripheral blood monocytes with their subsequent incubation (transimmunization) led to a 30% decrease of serum TNF-α in patients with multiple sclerosis. This indicates a suppressive effect of transimmunization on TNF-α. Hence, in patients with multiple sclerosis transimmunization exerts an anti-inflammatory effect.

About the authors

A. V. Kil'dyushevskiy

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, PhD, Professor, Leading Research Fellow, Surgical Hemocorrection and Detoxication Department

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

S. V. Kotov

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: kotovsv@yandex.ru

MD, PhD, Professor; Head of Department of Neurology; Head of Chair of Neurology, Postgraduate Training Faculty

61/2–10 Shchepkina ul., Moscow, 129110

Tel.: +7 (495) 631 73 62

Russian Federation

O. P. Sidorova

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, PhD, Professor, Leading Research Fellow, Department of Neurology; Chair of Neurology, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

A. V. Borodin

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, Neurologist, Department of Neurology

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

References

  1. Lorré K, Fransen L, Ceuppens JL. Interleukin-2 induces tumor necrosis factor-alpha production by activated human T cells via a cyclosporin-sensitive pathway. Eur Cytokine Netw. 1992;3(3):321–30.
  2. Benvenuto R, Paroli M, Buttinelli C, Franco A, Barnaba V, Fieschi C, Balsano F. Tumour ne￾crosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis. Clin Exp Immunol. 1991;84(1):97–102.
  3. Piotrowska K, Korlak J, Kruszewska J, Iwińska B, Członkowska A. Secretion of tumor necrosis factor alpha (TNF-alpha) by peripheral blood monocytes in patients with multiple sclerosis and subacute sclerosis panencephalitis. Neurol Neurochir Pol. 1991;25(4):455–9.
  4. Ruffini F, Chojnacki A, Weiss S, Antel JP. Immunobiology of oligodendrocytes in multiple sclerosis. Adv Neurol. 2006;98:47–63.
  5. Вострякова СА, Алифирова ВМ, Иванова СА, Орлова ЮЮ. Апоптоз лимфоцитов у больных рассеянным склерозом. Бюллетень сибирской медицины. 2008;7 Прилож. 1: 200–3. 6.Obradović D, Kataranovski M, Dincić E, Obradović S, Colić M. Tumor necrosis factor-alfa and interleukin-4 in cerebrospinal fluid and plasma in different clinical forms of multiple sclerosis. Vojnosanit Pregl. 2012;69(2):151–6.
  6. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10):1885–8.
  7. Andreadou E, Kemanetzoglou E, Brokalaki Ch, Evangelopoulos ME, Kilidireas C, Rombos A, Stamboulis E. Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med. 2013;2013:671935. doi: 10.1155/2013/671935.
  8. Balsalobre Aznar J, Porta-Etessam J, Salvatierra Ossorio J, Rosales-Alexander JL. Tumor necrosis factor-alpha antagonist and demielynating diseases. J Neurol Neuroscience. 2013;4(3):2–6. doi: 10.3823/339.
  9. Honda Y, Otsuka A, Egawa G, Inoue Y, Kuzuya A, Takahashi R, Miyachi Y, Kabashima K. Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-α therapy in psoriatic arthritis. Eur J Dermatol. 2015;25(5):487–8. doi: 10.1684/ejd.2015.2558.
  10. Cavaletti G, Perseghin P, Dassi M, Oggioni N, Sala F, Braga M, Lolli F, Riccio P, Carlone G, Zoia C, Tagliabue E, Stanzani L, Galbiati S, Rigamonti L, Marmiroli P, Ferrarese C, Frattola L, Tredici G. Extracorporeal photochemotherapy reduces the severity of Lewis rat experimental allergic encephalomyelitis through a modulation of the function of peripheral blood mono￾nuclear cells. J Biol Regul Homeost Agents. 2004;18(1):9–17.
  11. Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfus Apher Sci. 2002;26(3):181–90. doi: 10.1016/S1473-0502(02)00011-3.

Copyright (c) 2016 Kil'dyushevskiy A.V., Kotov S.V., Sidorova O.P., Borodin A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies